@article{8a70250f70c0488593a12c0e3f4650b5,
title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update",
abstract = "This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2–3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.",
author = "Johnson, {J. A.} and Caudle, {K. E.} and L. Gong and M. Whirl-Carrillo and Stein, {C. M.} and Scott, {S. A.} and Lee, {M. T.} and Gage, {B. F.} and Kimmel, {S. E.} and Perera, {M. A.} and Anderson, {J. L.} and M. Pirmohamed and Klein, {T. E.} and Limdi, {N. A.} and Cavallari, {L. H.} and M. Wadelius",
note = "Funding Information: This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264) and PharmGKB (R24GM61374). Relevant funding for other authors includes: NIH grants U01 GM074492 and U01 HG 007269 (JAJ), K23GM104401 (SAS), GM109145 (CMS), R01HL092173 and K24HL133373 (NAL), R01 HL097036 (BFG) and grants from the Swedish Research Council (Medicine 521-2011-2440 and 521-2014-3370), the Swedish Heart and Lung Foundation (20120557 and 20140291), and the Thur{\'e}us' Foundation (MW), the UK Department of Health and Medical Research Council (MP), and the EU FP7 programme for funding EU-PACT (MP, MW). Publisher Copyright: {\textcopyright} 2017 American Society for Clinical Pharmacology and Therapeutics",
year = "2017",
month = sep,
doi = "10.1002/cpt.668",
language = "English",
volume = "102",
pages = "397--404",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
number = "3",
}